# FDA 483 - Ann R. Woodbridge, M.D. - January 24, 2022

Source: https://www.globalkeysolutions.net/records/483/ann-r-woodbridge-md/327fdeb4-c1e0-49a0-a236-246abfb98c61

> FDA 483 for Ann R. Woodbridge, M.D. on January 24, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Ann R. Woodbridge, M.D.
- Inspection Date: 2022-01-24
- Product Type: drugs
- Office Name: Division of Human and Animal Food Operations - West III
- Summary: An FDA inspection of Ann R. Woodbridge, M.D., a clinical investigator in Dallas, TX, revealed a significant deviation from the investigational plan. The firm failed to ensure timely submission of bone mineral density scans, leading to delays in identifying and discontinuing subjects who met withdrawal criteria from a study. This indicates a failure to adhere to study protocols and ensure subject safety and data integrity.

## Related Officers

- [investigator](https://www.globalkeysolutions.net/people/travis-m-beard/a89f6d0b-dc5b-4adc-84f5-36e04b00fc2d)

Company: https://www.globalkeysolutions.net/companies/ann-r-woodbridge-md/b96db387-acb2-43f8-8520-236f3c0cc8db

Office: https://www.globalkeysolutions.net/offices/division-of-human-and-animal-food-operations-west-iii/2cda09a5-06c4-433f-9df0-0d7903a6efab